Farnesoid X receptor (FXR) is a ligand-activated nuclear receptor that plays a central role in regulating genes involved in bile acid homeostasis, and fat and glucose metabolism. Here, we demonstrate a post-translational interplay between FXR phosphorylation, SUMOylation, and ubiquitination that directs the receptor into an activation-degradation pathway in hepatocytes. We identify a non-canonical SUMOylation motif termed pSuM that conjugates SUMO2 at Lys-325 of FXR under the direct control of casein kinase 2 (CK2), which provides the required negative charge for Ubc9 and PIAS1 to perform SUMOylation, by phosphorylating Ser-327. Lys-325 SUMOylation is indispensable to the promotion of efficient ligand activation and transcriptional coactivation of FXR. Constitutive pSuM activation using a phospho-mimic Ser-327 mutant or catalytic CK2 expression strongly induces SUMO2 conjugation, which directs FXR ubiquitination and proteasome-dependent degradation. We also determine that such SUMOylation-dependent ubiquitination of FXR is mediated by the E3 ubiquitin ligase RNF4, which is required to achieve maximal induction of FXR and optimal up-or downregulation of responsive genes involved in bile acid homeostasis and liver regeneration. Our findings identify a highly regulated atypical SUMO conjugation motif that serves to coordinate FXR transcriptional competence, thereby expanding the intricate dynamics of the SUMOylation process used by incoming signals to govern metabolic gene regulation.
Introduction
Bile acids are amphipathic molecules that facilitate the efficient solubilization and intestinal absorption of dietary lipids, cholesterol, and fat-soluble vitamins. In addition, de novo synthesis of bile acids is a major pathway for cholesterol elimination from the body. The farnesoid X receptor (FXR; NR1H4) is a member of the nuclear receptor superfamily that directly interacts with bile acids to regulate critical genes involved in bile acid synthesis, conjugation, detoxification, and flux (Mangelsdorf et al., 1995) . Besides its important role in bile metabolism, FXR also emerges as a key regulator of fat and glucose homeostasis and inhibits the inflammatory response in liver and intestine (Lefebvre et al., 2009; Calkin and Tontonoz, 2012; Hollman et al., 2012) , which makes FXR a promising therapeutic target for cholestasis disorders, chronic inflammation, diabetes, and other complications of the metabolic syndrome. Deciphering the mechanistic control of FXR activity is therefore important in our understanding of FXR beneficial actions.
For transcriptional activation of target genes, FXR binds to FXR response elements (FXRE) as a heterodimer with the retinoid X receptor RXR upon interaction with endogenous bile acids, such as chenodeoxycholic acid (CDCA) and cholic acid. In addition to inducing gene expression directly, FXR mediates the repression of a number of genes indirectly through the regulation of SHP (NR0B2), an atypical orphan nuclear receptor (Goodwin et al., 2000; Lu et al., 2000) . As part of the intricate transcriptional mechanisms involved in regulating such a wide spectrum of genes by FXR and by other nuclear receptors, a number of post-translational modifications have been described to ensure proper response to ligand and/or to other cellular signals. Among them, SUMOylation, which consists of conjugating ubiquitin-like SUMO proteins, can promote a wide variety of cellular outcomes by regulating positively or negatively the transcription potential of nuclear receptors (Treuter and Venteclef, 2011) . The diversity of the SUMOylation process and functional consequence is determined by a monomeric conjugation of substrates using SUMO1, or by generating, as with ubiquitin, polymeric chains with SUMO2 and SUMO3. In most cases, covalent modification by SUMO takes place on an accepting lysine residue within the minimal consensus motif ψKxE/D, where ψ represents a bulky hydrophobic amino acid (Rodriguez et al., 2001) . Two extensions to the core SUMOylation motif have been described to enhance substrate SUMOylation with the presence of a flanking cluster of acidic residues (Yang et al., 2006) or by proline-directed phosphorylation of an adjacent serine residue (Hietakangas et al., 2006) . In both cases, the extension provides a negatively charged patch that would allow a more efficient recruitment of E2 conjugase Ubc9 to promote SUMOylation, such as demonstrated for Elk-1 (Yang et al., 2006) . Recently, we identified a novel variation of the SUMOylation motif in estrogen receptor β (ERβ; NR3A2) in which both the core motif and its extension are regulated by direct phosphorylation (Picard et al., 2012) . This atypical recognition site termed pSuM consists of the sequence ψKxS, which becomes fully competent in conjugating SUMO1 to ERβ upon phosphorylation of its contained serine, thus providing the necessary negative charge for SUMOylation. This process was further enhanced by phosphorylation of adjacent serine residues by GSK-3β, which maximizes ERβ SUMOylation in response to hormone, providing a mechanism for ERβ regulation by activated kinase pathways (Sanchez et al., 2010; Picard et al., 2012) .
Evidence that FXR is a target of SUMOylation initially came from studies characterizing the anti-inflammatory effects of FXR. FXR and HA-SUMO2 expression plasmids and immunoprecipitation was carried out with an anti-FXR antibody, and bound proteins were analysed by western blot with an anti-HA antibody. FXR was also analysed using an anti-GFP antibody (bottom). Ubc9 and PIAS1 plasmids were also added as indicated and input levels determined by western blot analysis of whole cell extracts. (B) Immunoprecipitation assay performed as described in A, except that plasmids for wild-type SENP1, for the catalytically inactive SENP1 C603S mutant, or for SUMO2 lacking the di-glycine attachment motif were added. Input levels of Ubc9 and SENP1 are also shown. (C) Same as in A, except that cells were also treated for 5 h with 1 μM FXR agonist GW4064. (D) SUMOylation assay performed in HepG2 cells treated or not with 1 μM GW4064. FXR was immunoprecipitated as in A and extracts analysed using an anti-SUMO2 antibody. (E) Transcriptional activation of FXR by SUMO2. 293 cells were transfected with a Gal4-FXR fusion in the presence of a UAStkLuc reporter and increasing amounts (0-200 ng) of SUMO2 plasmid. Cells were then treated or not with 1 μM GW4064 for 16 h. Results are expressed as fold response compared to untreated cells set at 1.0.
SUMOylation of FXR at Lys-277, one of the two consensus sites with Lys-122 for SUMO addition, was shown to mediate the trans-repression of pro-inflammatory genes, such as TNFα, although no further evidence of direct Lys-277 SUMOylation was presented (Vavassori et al., 2009) . FXR Lys-277 and Lys-122 have been identified as direct targets of SUMO1 in hepatocytes, modulating FXR ligand-dependent binding and expression of target genes, such as BSEP and SHP (Balasubramaniyan et al., 2013) . More recently, acetylation of FXR was shown to inhibit SUMO2 modification at Lys-277, resulting in trans-activation of inflammatory genes without affecting classical FXR/RXR target genes, thus revealing an acetyl/SUMO switch of FXR with link to hepatic inflammation (Kim et al., 2015) . These studies highlight the importance of consensus SUMOylation at typical sites in regulating FXR transcriptional competence and target gene expression.
Here, we identify Lys-325 as a non-canonical site of SUMOylation of human FXR, which is part of a pSuM motif located near the AF-2 domain responsible for transcriptional coactivation. Consistent with the intrinsic nature of the pSuM, we identify casein kinase CK2 as the priming effector that phosphorylates Ser-327, resulting in enhanced SUMO2 conjugation, which then directs the ubiquitination and degradation of FXR through the recruitment of the SUMO-dependent ubiquitin E3 ligase RNF4. Our results define a highly regulated atypical SUMOylation process that coordinates posttranslational modifications of FXR to achieve efficient target gene regulation.
Results

FXR is modified by SUMO2
We first addressed the SUMOylation of FXR by transfecting human embryonic kidney 293 cells with a human FXRα1 construct and performed immunoprecipitation and western blot analysis. Addition of SUMO2 revealed a specific higher molecular weight band pattern indicative of polySUMOylation ( Figure 1A and Supplementary Figure S1A) , consistent with the nature of SUMO2 to form SUMOylation chains and of previous reports also describing FXR SUMOylation (Balasubramaniyan et al., 2013; Kim et al., 2015) . The intensity of the polySUMOylation was increased with expression of Ubc9, the obligate E2 SUMO conjugase, and E3 ligase PIAS1, either expressed alone or in combination, suggesting a role for PIAS1 in FXR SUMOylation. The specificity of FXR SUMOylation was further addressed with the addition of deSUMOylase SENP1 or SENP2, and with a conjugation-deficient SUMO2-ΔGG mutant which both abolished FXR SUMOylation, whereas the inactive SENP1 C603S mutant had no effect ( Figure 1B and Supplementary Figure S1A) . FXR SUMOylation was increased in response to FXR synthetic agonist GW4064 ( Figure 1C and D) and to natural bile acid CDCA (Supplementary Figure S1B) in transfected 293 cells and HepG2 hepatocytes, indicating that FXR SUMOylation is a highly regulated process modulated by activation signals targeting FXR. To address the impact of SUMO2 on FXR activity, we performed one-hybrid luciferase reporter assays, which demonstrate that ectopic expression of SUMO2 enhanced the intrinsic transcriptional potential of FXR in the presence of ligand ( Figure 1E ). These results indicate that FXR is a specific substrate of SUMO2 that regulates its activity.
Non-consensus pSuM Lys-325 is targeted by SUMO2
Previous studies that described FXR SUMOylation have identified two potential accepting sites, Lys-122 and Lys-277, for SUMO modification (Vavassori et al., 2009; Balasubramaniyan et al., 2013; Kim et al., 2015) . This was based primarily on mutagenesis of the canonical consensus SUMO conjugation motif ψKxE/D found in two locations in FXR protein. We thus mutated both Lys-122 and Lys-279 (which corresponds to Lys-277 in mouse) of human FXRα1, which led to a decrease in FXR SUMOylation, in accordance with their identification as target sites of SUMO2 ( Figure 2A and Supplementary Figure S2A) . However, FXR-SUMO2 conjugation was not completely abolished with the K122,279R mutation, suggesting the potential role of other site(s) implicated in FXR SUMOylation. FXR contains a non-consensus SUMOylation site at position 325, which is part of an atypical SUMO conjugation motif termed pSuM (Picard et al., 2012) , suggesting that this lysine residue may also serve as an accepting site for SUMO addition. The pSuM was originally identified in nuclear receptor ERβ (Picard et al., 2012) , and consists of the sequence ψKxS, in which the usual acidic residue at +2 from the accepting lysine is replaced with a phosphorylated serine providing the obligate negative charge to recruit and position Ubc9 ( Figure 2B ). We therefore tested the potential of FXR SUMOylation at pSuM Lys-325 and found that the K325R mutation severely impaired the effect of Ubc9 and PIAS1 on SUMO2 conjugation when compared to wild-type ( Figure 2C ). Consistent with pSuM activation, replacement of Ser-327 with an aspartic residue (S327E) which provides a negative charge and mimic a consensus SUMOylation motif (i.e. LKGE sequence) led to an increase in SUMO2 conjugation levels compared to wild-type and to S327A mutant ( Figure 2D ). The S327E mutant also exhibits enhanced SUMOylation in HepG2 hepatocytes ( Figure 2E and Supplementary Figure S2B ). To further determine Lys-325 as an accepting site, we performed in vitro SUMOylation in the presence of adenosine triphosphate (ATP) and purified components of the SUMO pathway. FXR and the S327E mutant were found highly modified by SUMO2, while disruption of Lys-325 (K325R) strongly impaired FXR SUMOylation ( Figure 2F) . Again, mutation of the two consensus SUMOylation sites (K122,279R) strongly diminished but did not abolish FXR-SUMO2 levels in conditions of pSuM activation (S327E), consistent with additional SUMOylation at Lys-325. Similarly, S327E mutation promoted FXR SUMOylation in the context of K122,279R mutation in transfected 293 cells and HepG2 hepatocytes (Figure 2A and Supplementary Figure S2A) . In transactivation assay, disruption of pSuM Lys-325 strongly impaired the ligand activation of FXR and the potential of SUMO2 to activate the receptor ( Figure 2G ). These results identify Lys-325 as a target of SUMO and define the pSuM as a functional SUMO-accepting site in FXR. 
The pSuM is involved in the response of FXR to transcriptional coactivators
To gain insights on the structural basis of the pSuM in respect to the active conformation of FXR, we took advantage of the reported crystallographic structure of the LBD of FXR in the presence of CDCA ligand and coactivator SRC2 peptide (PDB ID: 4QE6). Lys-325 is located in helix 4 of FXR and appears highly accessible to the solvent, with its side chain protruding outbound from the periphery of the LBD, hence supporting an open access to SUMO modification ( Figure 3A ). In addition, Lys-325 is in close vicinity of the AF-2 helix 12 and SRC2-interacting motif involved in ligand-dependent activation of the receptor ( Figure 3B ). We thus determined the impact of disrupting Lys-325 on the response of FXR to various transcriptional coactivators and found that the potential of steroid receptor coactivator/nuclear receptor coactivator (SRC), CREB-binding protein (MED1), and mediator complex subunit 1 (CBP) coactivators to activate FXR was significantly impaired with the K325R mutation ( Figure 3C and Supplementary Figure S3 ). Intriguingly, we also observed that the K325R mutant was more prone to corepressor nuclear receptor corepressor-2 (NCoR2)/SMRT mediated inhibition, probably reflecting a reduced potential to be coactivated and/or increased recruitment of NCoR2. These results suggest that pSuM SUMOylation is required to achieve optimal FXR activation.
CK2 is required to mediate FXR pSuM SUMOylation
The molecular basis for a functional pSuM to promote SUMOylation of substrates is provided by the requisite phosphorylation of the serine residue at +2 from the accepting lysine. We then addressed the cellular signal responsible for such phosphorylation and found that Ser-327 of FXR is part of a canonical SxxE/D consensus site for casein kinase 2 (CK2) highly conserved in several species ( Figure 2A) . We thus addressed the role of CK2 by first treating cells with increasing concentrations of the CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) and found that in these conditions SUMO2 shows that Lys-325 residue is located in helix 4 and is in close proximity of the helix 12 (AF-2) and SRC2 interaction motif. (C) The transcriptional response of FXR to coactivators is altered by the K325R mutation. Luciferase assay was performed in 293 cells transfected with FXR and RXRα in the presence of SHPbLuc reporter that contains the proximal promoter of the SHP gene. Transcriptional coregulators (SRC, CBP, MED1, and NCoR2) were also added and cells were treated or not (vehicle) with 1 µM GW4064 for 18 h. Results are expressed as fold response compared to untreated cells in the absence of coregulators set at 1.0. *P < 0.05 wt FXR vs. K325R. conjugation to FXR was strongly impaired ( Figure 4A) . Consistent with such effect, we also observed a potent increase of FXR SUMOylation in response to expression of the catalytic CK2α1 subunit ( Figure 4A ). In addition, the inhibitory effect of TBB on SUMO2 modification of FXR was prevented with the S327A mutation ( Figure 4B ), suggesting that Ser-327 is needed. CK2 also increased FXR transcriptional activation to GW4064 and to SUMO2 expression ( Figure 4C and Supplementary Figure S4 ), while the S327A remained unresponsive to CK2 expression or TBB inhibition ( Figure 4C and D) . To determine the potential of FXR Ser-327 to undergo phosphorylation by CK2, cells were transfected with a fragment of FXR corresponding to aa 315-345 region of helix 4/5 which contains the pSuM, and analysed by western blot using a phospho-specific antibody against the CK2 consensus pS/pTxxE site. Results showed a strong phosphorylation at Ser-327, which was enhanced in response to expression of constitutive CK2α, and abolished by TBB inhibitor and by S327A mutation ( Figure 4E ), indicating that Ser-327 is a CK2 target site. These results identify a contributing role of CK2 in promoting FXR-SUMO2 conjugation at the pSuM ( Figure 4F ) and enhancing FXR transcriptional activity through Ser-327 phosphorylation.
SUMO2 modification at Lys-325 regulates FXR degradation
Nuclear receptor transcriptional modulation is tightly linked to their degradation mostly involving the ubiquitin-proteasome pathway and SUMOylation has been described to participate in that process for nuclear receptors (Nawaz and O'Malley, 2004;  SUMOylation assay of FXR was performed in response to increasing expression of the catalytic CK2α1 subunit. Cells were also treated with 2 and 10 µM of CK2 inhibitor TBB for 6 h. Input levels of CK2 are shown. (B) Similar as in A except that S327A mutant was compared to wild-type FXR. Cells were treated with 10 µM TBB. (C) CK2 increases the transcriptional activity of FXR. Luciferase assay were performed in 293 cells transfected with Gal4 constructs of FXR wild-type and S327A mutant in the presence of UAStkLuc reporter and CK2α1. Cells were also treated or not with 1 μM GW4064 for 18 h. *P < 0.05. (D) 293 cells were transfected with FXR (wt or S327A) and RXRα and luciferase assay was determined on a SHPbLuc reporter. Cells were treated with 1 µM GW4064 and 2 µM TBB inhibitor for 18 h. *P < 0.05. (E) CK2 phosphorylates FXR at Ser-327. 293 cells were transfected with a tagged fragment of FXR corresponding to aa 315-345 position of helix 4/5 which contains the pSuM, and compared to the same fragment bearing the S327A mutation. Cells were also transfected with CK2α1 catalytic subunit or treated with 2 µM TBB for 6 h and then harvested for immunoprecipitation and analysed by western blot using an antibody that recognizes the phosphorylated CK2 consensus pS/pTxxE sequence. (F) Schematic representation of FXR pSuM. Ser-327 of the pSuM is phosphorylated by CK2 to allow proper SUMO2 conjugation to accepting Lys-325. Karamouzis et al., 2008; Lonard and O'Malley, 2009; Picard et al., 2012) . To explore the functional consequences of SUMO2 modification on FXR receptor turnover, we tested the contribution of the pSuM on receptor protein levels and degradation. Increasing SUMO2 expression led to a reduction in steady-state levels of FXR in cells ( Figure 5A and Supplementary Figure S5A) . However, the levels of pSuM defective mutant K325R were less affected in the absence or presence of ligand, suggesting that FXR stability is regulated by pSuM SUMOylation ( Figure 5A and Supplementary Figure S5B ). In addition, the phospho-mimic S327E pSuM mutation decreased FXR levels when compared to S327A mutant and to wild-type receptor ( Figure 5B and Supplementary Figure S5C) . In each case, protein levels were strongly increased with proteasome inhibitor MG132, providing a role of the 26S ubiquitin-proteasome system in FXR degradation by SUMO2. To ascertain the effect of SUMOylation on FXR degradation, we performed cycloheximide chase experiments that revealed a significant decrease in receptor stability for the S327E mutant (t 1/2~1 .5 h) compared to wild-type FXR (t 1/2~4 h) ( Figure 5C ). These results support a role of SUMOylation at the pSuM in regulating FXR degradation.
FXR SUMOylation interplays with ubiquitination
Based on the potential of pSuM SUMOylation to affect FXR degradation and on the role of the 26S proteasome in that process, we next analysed the ubiquitination of FXR. We observed that FXR was strongly ubiquitinated in basal conditions and that increasing exposure to GW4064 led to a reduction in ubiquitination levels ( Figure 6A ), suggesting that activation of FXR is linked to its de-ubiquitination. Such ubiquitination/de-ubiquitination process appears to be essential to achieve FXR maximal activation to ligand as addition of MG132 completely abolished the transcriptional response of FXR ( Figure 6B ), indicating the requirement of a functional proteasome degradation pathway for FXR activation. To explore the role of elevated pSuM SUMOylation on FXR ubiquitination, we then tested the effect of SUMO2 overexpression and observed a dose-dependent increase of FXR ubiquitination ( Figure 6C) . Consistent with such effect of SUMO2, addition of SENP1, which strongly reduced FXR SUMOylation ( Figure 1B and Supplementary Figure S1A) , further decreased FXR ubiquitination levels in the presence or absence of ligand ( Figure 6D ). This suggests that enhanced SUMOylation may serve as a signal to ubiquitinate FXR. To ascertain the direct role of the pSuM in that process, the SUMOylation-inducing S327E mutation completely abolished the ligand-dependent de-ubiquitination of FXR and even increased basal ubiquitination of the receptor ( Figure 6E) . Similarly, enhanced basal ubiquitination levels of FXR and loss of de-ubiquitination effect of GW4064 were observed for the S327E pSuM activation mutant in HepG2 hepatocytes ( Figure 6F ). In addition, the disrupting K325R and S327A pSuM mutations relieved the ligand-dependent de-ubiquitination of FXR ( Figure 6F ), linking pSuM activity to FXR ubiquitination. Moreover, CK2 expression augmented FXR ubiquitination (Supplementary Figure S6) and decreased the steady-state levels of FXR in a proteasome-dependent manner ( Figure 6G ), correlating with enhanced receptor degradation in conditions of activated pSuM. These results are consistent with the increased turnover and degradation of the receptor in the context of activated pSuM activity, and identify the pSuM as a convergent signal recognition motif to regulate both FXR SUMOylation and ubiquitination processes.
The E3 ligase RNF4 is required to ubiquitinate FXR in response to pSuM SUMOylation
Our results suggest that SUMO2 conjugation to FXR might serve as a signal to promote its ubiquitination. SUMO-induced ubiquitination, also known as STUbL activity, generally requires substrate recognition by an E3 ubiquitin ligase through SUMOinteracting motifs or SIMs. The canonical STUbL RNF4 has been shown to bind preferentially SUMO2/3 conjugates, such as PML and its oncogenic variant PML-RARα, via tandem SIM repeats to induce their ubiquitination and degradation (LallemandBreitenbach et al., 2008; Tatham et al., 2008) . We thus explore the interesting possibility that RNF4 could recognize SUMO2-FXR to mediate its ubiquitination. We found that both basal and liganded FXR ubiquitination levels were increased in response to ectopic expression of RNF4 ( Figure 7A ), correlating with a marked reduction of FXR protein levels ( Figure 7B ). In addition, expression of a dominant negative RNF4 C132,135S mutant, in which mutation of the zinc-coordinating cysteine residues in the RING domain abolishes E3 ligase activity, markedly reduced FXR ubiquitination in cells ( Figure 7C ). These results suggest that FXR is a target of RNF4 resulting in receptor ubiquitination and degradation. We then addressed the role of pSuM SUMOylation in the potential of RNF4 to ubiquitinate FXR and found that the RNF4-mediated increase in FXR ubiquitination was impaired with the SUMO-defective K325R mutation ( Figure 7D) . Also, the K325R mutant remained mostly unresponsive to the dominant negative RNF4 C132,135S mutant with no change in ubiquitination levels ( Figure 7C ). These results indicate that pSuM SUMOylation is required to induce FXR ubiquitination by RNF4.
RNF4 is required to optimize FXR transcriptional activity in hepatocytes
Because proteasome activity was found essential to maximize FXR activation to ligand ( Figure 6B ), we next addressed the impact of RNF4 on the transcriptional potential of FXR. In luciferase assays, overexpression of RNF4 further induced the activation of FXR to GW4064 in HepG2 and Huh-7 hepatocytes ( Figure 7E and Supplementary Figure S7A) . Similar results were also obtained in transfected 293 cells (Supplementary Figure S7B) . These findings suggest that RNF4-mediated ubiquitination is required for maximal transcriptional response of FXR. Such enhancement of ligand activation by RNF4 was abolished with the K325R mutation ( Figure 7E and Supplementary Figure S7 ), which also impairs transcriptional activity compared to wild-type receptor, thereby supporting an essential role of pSuM SUMOylation in FXR transcriptional competence. Consistent with this, shRNA knockdown of RNF4 in HepG2 cells decreased the response of FXR to GW4064 agonist, while the K325R mutant remained unresponsive ( Figure 7F ). In addition, RNF4 is shown to co-immunoprecipitate with FXR in a manner further potentiated by agonist, indicating an enhanced recruitment of RNF4 to activated FXR ( Figure 7G ). Optimal regulation of FXR target genes involved in bile acid homeostasis also required normal RNF4 activity as knockdown of RNF4 resulted in greatly impaired upregulation of FXR target genes, such as FGF19, SHP, and BSEP genes in HepG2 hepatocytes ( Figure 7H) . Interestingly, expression of CYP7A1, encoding the rate-limiting enzyme of bile acid synthesis and normally downregulated by FXR via SHP repression (Goodwin et al., 2000; Lu et al., 2000) , was stimulated with RNF4 knockdown ( Figure 7H) . Similarly, the repression of ABCA1 described to result from FXR induction of miRNAs targeting the ABCA1 gene (Tarling et al., 2015) was also impaired with RNF4 knockdown. Besides protection from bile acid toxicity, FXR activation has also been linked with liver growth and regeneration to maintain proper liver capacity function with regulation of transcription factor FoxM1 and downstream genes in particular (Huang et al., 2006; Zhang et al., 2012) . Interestingly, while FOXM1 gene expression was slightly upregulated by GW4064, significant responses of SKP2 a target gene of FOXM1, as well as of CDKN1A (p21 Cip1 ) and CDKN1B
( p27 Kip1 ), known to be downregulated to FOXM1 activation, were strongly impaired by shRNF4 knockdown ( Figure 7H) . Similar results were also obtained for CCND1 and CEBPB (C/ EBPβ), also required to promote liver growth and regeneration. This indicates that RNF4 is essential for both FXR-mediated up-and downregulation of responsive genes involved in various aspects of FXR activity. Collectively, these results identify RNF4 as an essential effector of FXR function, regulating its transcriptional activity and ubiquitination in response to phosphorylation-dependent SUMOylation.
Discussion
In this study, we identify nuclear receptor FXR as a SUMOylated target conjugating SUMO2 at the accepting lysine 325 residue embedded into a non-consensus ψKxS SUMOaccepting motif known as the pSuM. We show that this atypical SUMOylation site is highly conserved and diverges from the core consensus ψKxE sequence, as it requires prior phosphorylation of Ser-327 by CK2, providing the necessary negative charge to promote FXR SUMOylation. This identifies CK2 as a priming event for induced SUMOylation that leads to an increase in FXR turnover through a SUMOylation-dependent ubiquitination of the receptor mediated by the E3 ligase RNF4, as depicted in Figure 8 . This study uncovers a post-translational modification cascade involving phosphorylation, SUMOylation and ubiquitination under the control of a CK2-RNF4 interplay that is required for transcriptional regulation of FXR targeted genes.
Our identification of Lys-325 as a new SUMO-accepting site in human FXR is adding complexity to the already reported SUMOylation process of FXR. Indeed, Lys-122 and Lys-277 (279 in human) have been described as targets contained in consensus SUMO recognition motifs that modulate FXR activity (Vavassori et al., 2009; Balasubramaniyan et al., 2013; Kim et al., 2015) . Specifically, ligand-induced SUMOylation of Lys-277 has been shown to mediate FXR trans-repression of Cycloheximide chase experiments using 293 cells expressing FXR wild-type or S327E mutant. Cells were analysed by western blot at the indicated times after cycloheximide addition. β-actin was used as a loading control. Results are expressed as the percent change from time 0, which was set at 100%. *P < 0.05; **P < 0.01 wt FXR vs. S327E.
inflammatory genes in mice while not affecting direct FXR targeted genes (Kim et al., 2015) . In that respect, our findings show that Lys-325 was essential to achieve a maximal response to ligand and transcriptional coactivators, suggesting that in such case, SUMOylation of the pSuM is required. The molecular basis for such difference is not known but it may depend on the respective location of each lysine in FXR. Lys-279 is located near the dimerization interface with RXR and thus could disrupt FXR-RXR dimer formation (Kim et al., 2015) , while Lys-325 is closer to the helix 12 and NCoA/SRC binding surface with the potential to directly affect AF-2 activity. However, in the case of Lys-325, we still have to determine whether SUMO2 addition might facilitate coactivator recruitment to FXR or if it is rather used as a transient step to direct receptor ubiquitination once transcription cycling is committed. In either case, the requirement of the ubiquitin-proteasome system appears essential to attain maximal activation of FXR, a process that was also evidenced for other nuclear receptors (Nawaz and O'Malley, 2004) .
The identification of a SUMO-accepting pSuM site within FXR is adding to the intricate nature of the SUMOylation process that regulates FXR transcriptional potential. SUMOylation has emerged as an important modification regulating positively or negatively the activity of several nuclear receptors with various consequences on their function and target gene expression (Treuter and Venteclef, 2011) . In most cases, SUMOylation takes place on a core consensus ψKxE/D motif that allows proper recruitment and position of Ubc9 to mediate conjugation of SUMO isoforms (Rodriguez et al., 2001) . Our identification of a functional pSuM brings another layer of regulation on the importance of SUMOylation in FXR transcriptional competence and target gene expression and moreover, it provides a signalling pathway by which phosphorylation can trigger receptor SUMOylation and activity by identifying CK2 as a priming kinase. SUMOylation enhancement by phosphorylation has been described for a subset of substrates including HSF (Hietakangas et al., 2006) , GATA1 (Collavin et al., 2004) , ERR (Vu et al., 2007; Tremblay et al., 2008) , and MEF2 (Gregoire et al., 2006) . In most cases, such regulation depends on phosphorylated residue(s) adjacent to the core SUMO-accepting sequence, referred to as the PDSM motif (Hietakangas et al., 2006) . In the case of FXR Lys-325 SUMOylation, the phosphorylated Ser-327 is located more proximal (at +2) of the conjugating lysine, replacing the acidic residue normally found at this position, while no other serine or threonine residues are found in close proximity in all examined species ( Figure 2B) . This excludes any possible role of Figure 7 RNF4 increases FXR ubiquitination and transcriptional activity in a SUMO-dependent manner. (A) RNF4 increases FXR ubiquitination. Ubiquitination assay in 293 cells transfected with FXR and HA-ubiquitin in the presence or absence of RNF4. Cells were treated or not with 1 μM GW4064 in the presence of 1 μM MG132 and then subjected to immunoprecipitation and western blot analysis. Input levels of RNF4 were determined by western blot analysis of whole cell extracts. (B) RNF4 decreases FXR protein levels. Western blot analysis performed on FXR in response to increasing concentrations of RNF4. Cells were treated or not with 1 µM GW4064. (C) Lys-325 is required for RNF4-mediated ubiquitination of FXR. Ubiquitination assay performed as in A except that FXR wild-type and K325R mutant were analysed in response to a dominant negative RNF4 C132,135S mutant. Cells were also treated or not with 1 μM GW4064. RNF4 input levels are shown. (D) Lys-325 is required for RNF4-mediated ubiquitination of FXR. Ubiquitination assay performed as in C in response to RNF4 expression. (E) RNF4 increases FXR transcriptional activity to ligand. HepG2 cells were transfected with Gal4-FXR wild-type and K325R mutant in the presence of RNF4 and UAStkluc reporter. Cells were then treated or not with 1 μM GW4064 and harvested for luciferase activity measurement. *P < 0.05. (F) Stable shRNF4 HepG2 cells generated by lentiviral infection were analysed as in E in luciferase assay and compared to control-infected (shCtl) cells. *P < 0.05. (G) RNF4 is recruited to FXR in a ligand-dependent manner. Co-immunoprecipitation assay in 293 cells transfected with FXR and RNF4 as indicated and treated with 1 µM GW4064. (H) RNF4 is required for optimal target gene regulation by FXR. Real-time PCR analysis was performed on FXR responsive genes in stable shRNF4 HepG2 cells treated or not with 1 μM GW4064. Results are normalized to RPLP0 expression and expressed as fold response compared to untreated shCtl cells, which was set at 1.0. *P < 0.05; **P < 0.02 shCtl vs. shRNF4.
a phosphorylated extension such as in the PDSM (Hietakangas et al., 2006) and the extended pSuM motif (Picard et al., 2012) for FXR. Therefore, it is presumed that phosphorylation of Ser-327 of FXR might provide the negatively charged microenvironment necessary to promote substrate recognition with Ubc9 basic patch and initiate SUMOylation at targeted lysine in a manner similar to the ψKxE motif as demonstrated by structural analysis (Mohideen et al., 2009) . Such buildup of negative charges can also come from a cluster of acidic residues flanking the ψKxE site that further potentiates SUMOylation, such as for Elk-1, PML, and LRH-1/NR5A2 (Yang et al., 2006) . Our identification of the pSuM as a novel SUMO recognition motif arises from studying the ERβ response to kinase signalling pathways (Sanchez et al., 2010; Picard et al., 2012) . Interestingly, although the basic mechanism for pSuM SUMOylation remains when comparing ERβ and FXR, it differs in other aspects of regulation. For instance, the ERβ pSuM is located at the far N-terminal end of the AF-1, a region highly sensitive to various kinase signalling pathways that drive ligand-independent activation of ERβ (Sanchez et al., 2010) . As such, the ERβ pSuM is activated in response to Erk-priming phosphorylation of the core motif and to GSK-3β mediated action on its tail (Picard et al., 2012) , whereas FXR needs CK2-directed phosphorylation without any specific role of a phosphorylated extension. Interestingly, as also demonstrated for ERβ, we observed that Lys-325 of FXR could also conjugate SUMO1 (data not shown), suggesting that the pSuM can direct both SUMO1 and SUMO2 addition. These findings highlight the dynamic nature of the SUMOylation process at the pSuM and expand the potential of priming signalling pathways in regulating nuclear receptor function.
Our study identifies CK2 as a novel regulator of FXR SUMOylation and activity. CK2 is considered a ubiquitously expressed kinase with many known substrates functioning in various cellular events, such as cell cycle regulation, apoptosis, viral infection, and transcriptional control (Meggio and Pinna, 2003; Duncan and Litchfield, 2008) . Although usually considered as a constitutive kinase, various effectors can regulate CK2, such as growth factors and oncogenic signals (Duncan and Litchfield, 2008; Montenarh, 2010) . In the context of FXR, we show that enhanced CK2 activity results in receptor phosphorylation at Ser-327, thereby promoting SUMOylation at the pSuM, transcriptional activation and degradation of FXR (Figure 8) . CK2 has been shown to trigger the ubiquitin-dependent degradation of PML in cancer cells through direct phosphorylation of PML (Scaglioni et al., 2006) . However, this process seems to differ from the one of FXR since prior SUMOylation of PML is required to then recruit CK2 and initiate ubiquitination (Rabellino et al., 2012) . To our knowledge, FXR is the first example underlying the ability of CK2 to trigger direct SUMOylation of its phosphorylated substrate. Interestingly, recent findings have linked CK2 with PIAS1 ability to recognize SUMO through direct phosphorylation of adjacent sites to PIAS1 SIM module, thereby enhancing the recruitment of free SUMO paralogs or conjugated substrates to PIAS1 (Stehmeier and Muller, 2009) . Such phosphoSIM modules have recently been described for transcriptional regulator Daxx (Chang et al., 2011) and BRCA subunit RAP80 (Anamika and Spyracopoulos, 2016) . With the role of PIAS1 to enhance pSuM SUMOylation of FXR, it is tempting to speculate that along with pSuM activation triggered by CK2 to add SUMO2 at Lys-325, CK2 activation might also promote the recruitment of PIAS1 to forming SUMO2-FXR to then reach optimal SUMOylation. How CK2 is a priori activated to modify FXR remains to be determined, but it is interesting to note that CK2 can itself be SUMOylated affecting its activity (Yao et al., 2011) . Our results indicate that such interplay between CK2 and the SUMO machinery is important for regulating FXR activity and degradation.
We identify RNF4 as a required component for achieving maximal transcriptional response of FXR to agonist. RNF4 is a Figure 8 Proposed model for FXR regulation by concerted actions of CK2 and RNF4. FXR conjugates SUMO2 at accepting Lys-325 following phosphorylation of Ser-327 by CK2 providing the required negative charge for Ubc9 action and full pSuM activity. This process is also optimized with the action of E3 ligase PIAS1 and the presence of FXR agonists such as GW4064 and bile acid CDCA. The process by which FXR agonist seems to first result in receptor de-ubiquitination is not known but enhancement of SUMO2 addition to FXR helps recruiting ubiquitin ligase RNF4 presumably through its recognized SIM motifs. Such recruitment of RNF4 is then required for efficient FXR activation in response to ligand and to transcriptional coactivators, and also promotes FXR ubiquitination and 26S proteasome-mediated degradation. It is proposed that this CK2-RNF4 interplay coordinates an activation-degradation cycling pathway that regulates FXR responsive genes.
SUMO-dependent E3 ubiquitin ligase (STUbL) known to interact preferentially with poly-SUMO2/3 chains via a cluster of repetitive hydrophobic SIMs, as demonstrated for PML, thus leading to its ubiquitination and degradation (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008) . Our results suggest that the SUMOylation triggered by CK2 and PIAS1 at Lys-325 might provide the necessary interface to recruit RNF4, resulting in FXR ubiquitination and degradation. This committed cascade of events defines a functional CK2-RNF4 interplay that is required for optimal transcriptional activation of FXR, supporting a transcription-degradation cycling mechanism for proper FXR function and identifying FXR as a novel target of RNF4 (Figure 8) . It remains to be determined whether RNF4-mediated ubiquitination of SUMO2-FXR is taking place on SUMO2 moiety and/or FXR itself, but in either case, the integrity of the pSuM is needed for optimal ubiquitination of FXR. Based on recent findings that RNF4 activity can be regulated by phosphorylation (Luo et al., 2015) , it would be interesting to determine whether CK2 can optimize RNF4 direct recruitment and ubiquitin ligase activity as a feed-forward mechanism to regulate FXR function.
Interestingly, both CK2 and RNF4 have independently been implicated in the response to cellular stress. For instance, oxidative stress was shown to enhance global SUMOylation of nuclear bodies-associated partners, precipitating their ubiquitination and proteasomal degradation upon activation of RNF4 (Rojas-Fernandez et al., 2014; Sahin et al., 2014) . This suggests a role of RNF4 as an effector of the adaptive response to cellular stress by degrading excess SUMOylated substrates. In addition, cellular stress, apoptosis inducers, and pro-inflammatory stimuli induce the activity of CK2 and promote its nuclear localization, conferring a protective role of CK2 in cell integrity (Kato et al., 2003; Unger et al., 2004) . FXR is known to regulate bile acid levels and xenobiotic metabolism by inducing detoxification enzyme genes (Hoffmann and Partridge, 2015) and has also been linked with the liver regeneration process to maintain optimal liver capacity with regulation of transcription factor FoxM1 and downstream genes for example (Huang et al., 2006; Zhang et al., 2012) . Our findings that target genes of FOXM1 and other genes known to be essential for liver growth and protection such as CCND1 and CEBPB (Li and Guo, 2015) were strongly impaired to FXR regulation in depleted conditions of RNF4, imply that RNF4 response to FXR SUMOylation is essential to maintain optimal different gene patterns controlled by FXR. Given the protective role of FXR in liver injury, inflammation and cholestatic disorders, the contribution of the CK2-RNF4 interplay on FXR fate and function might represent an attractive avenue to investigate in relation to metabolic diseases.
Material and methods
Plasmids
Tagged (HA-, YFP-) versions of the coding region of human FXRα1 have been constructed using pCMX-hFXR plasmid obtained from D. Mangelsdorf. All truncated and point mutants of FXR have been obtained by PCR mutagenesis using Pwo DNA polymerase (Roche) and verified by automated sequencing. The catalytic α subunit of CK2 was cloned from HepG2 cells and inserted into pCMX vector. Plasmids for HA-tagged SUMO2 (Mascle et al., 2007) , Ubc9, PIAS1, and SENP1 (Picard et al., 2012) , HA-tagged ubiquitin (Picard et al., 2008; Sanchez et al., 2013) , and RNF4 (Percherancier et al., 2009 ) have been described. The RNF4 C132,135S inactive mutant was generated as above.
Cell culture and transfection
Human embryonic kidney 293 cells were routinely maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 5% foetal bovine serum (FBS). Human liver hepatocellular carcinoma HepG2 and Huh-7 cells were cultured in DMEM containing 10% FBS. Transient transfections of cells were performed as described (Avallone et al., 2006) using calcium phosphate or polyethylenimine (Gibco). Treatments with FXR agonists GW4064 (1 μM; Tocris) and CDCA (50 μM; Sigma), and with CK2 inhibitor TBB (Calbiochem) were done in DMEM in the absence of serum for the indicated time periods.
Luciferase reporter assay
Luciferase assays were done as previously described (Avallone et al., 2006; Picard et al., 2008) using a UAStkLuc or a SHPbLuc reporter. The SHPbLuc reporter was generated by inserting the minimal promoter region of human SHP gene (positions −461 to +111) in front of the luciferase reporter gene. Values are normalized to the β-galactosidase activity and expressed as fold response compared to control. Data are derived from at least three independent experiments performed in triplicate.
Cell lysates and immunoblotting
FXR cellular content was determined by western blot analysis essentially as described (Picard et al., 2008) . Briefly, cells were transfected with HA-FXR and lysed in Tris-HCl buffer containing 1% Triton X-100, 0.1% sodium dodecyl sulphate (SDS), 0.1 M sodium chloride, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail (Roche). Immunoblot was performed using an anti-HA antibody (12CA5). Total protein loading was normalized using an anti-β-actin antibody (Novus Biologicals).
SUMOylation assay
Determination of SUMOylated FXR was performed essentially as described (Picard et al., 2012) . Briefly, cells were transfected with FXR or YFP-FXR in the presence of HA-SUMO2, Ubc9, and PIAS1 plasmids as indicated. Unconjugable form of SUMO2 (SUMO2ΔGG) or SUMO protease SENP1 was also used to inhibit SUMOylation. After treatments, the cells were harvested as described (Picard et al., 2012) in the presence of protease and phosphatase inhibitors (Roche), and N-ethylmaleimide (Sigma), and extracts were immunoprecipitated with an anti-FXR antibody (Santa Cruz Biotech). Western blot analysis was performed using antibodies either against GFP (Roche) or HA (12CA5).
In vitro SUMOylation assay
FXR wild-type and variants were produced using the TNT T7-coupled reticulocyte lysate system (Promega) and subjected to in vitro sumoylation reaction as described (Picard et al., 2012) . Typically, FXR proteins were incubated at 37°C for 1 h with E1 enzyme (SAE1/SAE2), E2 enzyme Ubc9, and SUMO2 (Boston Biochem) in the presence of 2.5 mM ATP. The reaction was stopped by adding an equal volume of Laemmli buffer, and the mixture was boiled. Samples were separated by SDS-PAGE and analysed by western blot using an anti-HA antibody.
Ubiquitination assay
Determination of FXR ubiquitination was performed essentially as described (Picard et al., 2008; Sanchez et al., 2013) . Cells were transfected with wild-type or mutated FXR in the presence of HA-tagged ubiquitin. Cells were then treated with vehicle, 1 μM MG132 (Enzo Life), and/or 1 μM GW4064 at indicated times and harvested for immunoprecipitation using an anti-FXR antibody (Santa Cruz). Extracts were analysed with an anti-HA antibody (12CA5), and input levels of FXR were normalized.
Cycloheximide chase
Cells were transfected with wild-type and mutated FXR. At 36 h after transfection, 50 μM cycloheximide (Sigma) was added and cells were harvested at the indicated time points. FXR steady-state levels were analysed by western blot. Results were derived from at least three separate experiments and expressed relative to β-actin levels.
RNA interference
Lentiviral shRNA knockdown of RNF4 was performed essentially as described (Sanchez et al., 2013) by infecting HepG2 cells. shRNAs were designed to target the sequence 5′-CATACTCCCAGAAACGCCAGG-3′ of human RNF4. Knockdown efficiency was monitored by qPCR and western blot. shCtl-infected cells were used as a negative control.
RNA isolation and qPCR analysis
Cells were treated with vehicle or 1 μM GW4064 for 16 h and RNA was extracted, reverse-transcribed and processed for PCR amplification as described (Rodrigue-Way et al., 2007) . Values are derived from at least two separate experiments performed in triplicate and normalized to ribosomal protein RPLP0 expression.
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